Bristol Myers Squibb has ended its partnership with Cellares, a company that builds automated manufacturing systems for cell therapies. According to Endpoints News, the pharma giant made the call after a "comprehensive evaluation" of the technology, and Cellares will restructure as a result.
At the center of the decision is Cellares' Cell Shuttle system. Endpoints News reports that Bristol Myers determined the system "could" — the outlet's account of the company's conclusion — fall short of what the drugmaker needed, and the partnership was terminated on that basis.
Some background helps explain the stakes. Cell therapies, including the CAR-T treatments that have become a major part of cancer care, are made by taking living cells, engineering them, and returning them to a patient. That process is slow, expensive, and largely hand-built inside specialized facilities. Companies like Cellares have pitched automation as the fix: machines that could produce these therapies faster, more consistently, and at greater volume than technicians working batch by batch.
That pitch depends heavily on validation from large pharmaceutical partners. A drugmaker of Bristol Myers' size signing on is both a revenue stream and a signal to the rest of the industry that the technology works at scale. Losing that partner cuts both ways, which is why a restructuring followed so closely behind the termination.
The details of what the restructuring involves, and how deep it goes, were not specified in the reporting available.
Why it matters: the promise of cheaper, faster cell therapies rests on automation actually working, and when a major buyer walks away after evaluating the hardware, it raises the question of whether that promise is arriving as quickly as the field has hoped.